Asia-Pacific is observing an ongoing rise in obesity and increased alcohol consumption that is primarily contributing to the growth of sleep apnea diagnostic and therapeutic devices.
The Asia Pacific sleep apnea diagnostic and therapeutic market is estimated to grow from $xx million in 2018 to $xx million by 2027, at a CAGR of 8.67% between 2019 and 2027.
China, Japan, India, Australia, South Korea, and the remaining countries collectively forming the Rest of Asia-Pacific are considered for the market analysis. China is the dominating market in the region alongside being the fastest growing sleep apnea diagnostic and therapeutic market in APAC mainly because of its large patient pool of the geriatric population.
Sleep apnea is widely prevalent in the elderly population and remains underdiagnosed owing to factors like lack of awareness amongst the people and non-specific presentation of the disease.
The major market players established in the APAC region are CareFusion (Merged With Becton Dickinson), Smiths Group PLC (Smiths Medical), Resmed Inc., Koninklijke Philips N.V. (Philips), Drive Devilbiss Healthcare, Somnomedics, Teleflex, Fisher & Paykel Healthcare, Invacare Corp., Braebon Medical Corporation, Cadwell, GE Healthcare, Itamar Medical Ltd., Nihon Kohden Corporation, and Medtronic PLC.